Stockscreener 앱 받기
0.5055
2.79%
-0.0145
Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스
Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed - Stock Titan
Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings - TradingView
Pasithea extends dose escalation for MEK inhibitor PAS-004 - Investing.com UK
Pasithea extends dose escalation for MEK inhibitor PAS-004 By Investing.com - Investing.com South Africa
Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies. - Bitget
Pasithea reports positive PAS-004 Phase 1 cancer data - grafa.com
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - Investing News Network
Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView
Price to book forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView
Pasithea Therapeutics Company Profile & Introduction - Moomoo
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Price to earnings forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Price to sales forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView
Pasithea Therapeutics Corp. Actuals & Estimates (NASDAQ:KTTA) - TradingView
KTTA Forecast — Price Target — Prediction for 2027 - TradingView
Pasithea Therapeutics Corp. Financial Disclosures & SEC Filings - TradingView
Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com - Investing.com South Africa
Stonepine Group reports 5.8% stake in Pasithea Therapeutics (KTTA) - Stock Titan
Major Investor Quietly Boosts Stake in Pasithea Therapeutics - TipRanks
Coastlands Capital LP acquires $53,000 of Pasithea stock - Investing.com UK
Coastlands Capital LP acquires $53,000 of Pasithea stock By Investing.com - Investing.com Australia
Form 4 Pasithea Therapeutics Corp For: 22 June By Investing.com - Investing.com Nigeria
Coastlands Capital LP (KTTA) adds 100,000 Pasithea Therapeutics shares in open-market buy - Stock Titan
Pasithea Therapeutics Corp (KTTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Institutional Confidence - TradingKey
Pasithea Therapeutics Corp (KTTA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pasithea Therapeutics Corp (KTTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pasithea Therapeutics Corp (KTTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pasithea Therapeutics Corp (KTTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pasithea Therapeutics Corp (KTTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pasithea Therapeutics Corp (KTTAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pasithea Therapeutics Corp (KTTAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pasithea Therapeutics Corp (KTTAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pasithea Therapeutics Corp (KTTAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pasithea Therapeutics Corp (KTTAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pasithea Therapeutics Corp (KTTAW) Institutional Confidence - TradingKey
Pasithea Therapeutics Corp (KTTAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT) - The Globe and Mail
Pasithea Therapeutics Corp (KTTAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pasithea Therapeutics Corp - TradingKey
Pasithea Therapeutics Corp (KTTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
KTTA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $3.00 - GuruFocus
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial - Investing News Network
Pasithea amends phase 1/1b trial protocol for PAS-004 in NF1 - Investing.com UK
Pasithea Therapeuticson Track to Release I - Moomoo
Pasithea expands PAS-004 clinical trial protocol - grafa.com
Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference - Investing News Network
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference - The Manila Times
Pasithea Therapeutics (KTTA) could find a support soon, here's why you should buy the stock now - MSN
Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesEPS Consistency Score - newsline.com
1.03%
2.69%
자본화:
|
볼륨(24시간):